NCT00415532View on ClinicalTrials.gov

Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura

PHASE3CompletedINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

December 1, 2006

Primary Completion Date

November 7, 2008

Study Completion Date

May 11, 2009

Conditions
Idiopathic Thrombocytopenic PurpuraThrombocytopeniaThrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)Thrombocytopenic Purpura
Interventions
DRUG

Medical Standard of Care for ITP

BIOLOGICAL

Romiplostim

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY